Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.68 |
| ▸ | HTR2A | P28223 | 8/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3134684 | 0.83 | SLC6A4 (0.75) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL19361290 | 0.82 | SLC6A4 (0.73) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL20852556 | 0.82 | SLC6A4 (0.73) | SLC6A4HTR2AKCNH2MAOASLC6A2 | |
| SCHEMBL6947509 | 0.81 | SLC6A4 (0.71) | SLC6A4HTR2AHRH3KCNH2SLC6A2 | |
| SCHEMBL19361237 | 0.81 | SLC6A4 (0.71) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL5878691 | 0.80 | SLC6A4 (0.56) | SLC6A4HTR2AHRH3KCNH2MAOA | |
| SCHEMBL6951883 | 0.80 | SLC6A4 (0.71) | SLC6A4HTR2AHRH3KCNH2SLC6A2 | |
| SCHEMBL6151957 | 0.80 | SLC6A4 (0.71) | SLC6A4HTR2AHRH3KCNH2SLC6A2 | |
| SCHEMBL6151954 | 0.80 | SLC6A4 (1.00) | SLC6A4HTR2AHRH3KCNH2SLC6A2 | |
| SCHEMBL5878563 | 0.80 | SLC6A4 (0.67) | SLC6A4HTR2AHRH3KCNH2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| WO-2010021681-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-02-25 | — | — | WO | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| EP-1268396-B1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6448293-B1 | TREATMENT OR PREVENTION OF A DISORDER IN WHICH THE REGULATION OF MONOAMINE TRANSPORTER FUNCTION IS IMPLICATED, SUCH AS PREMATURE EJACULATION. | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | ANDREWS MARK DAVID (GB) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | SLC6A4 34/4885HTR2A 10/4885HRH3 495/4885 |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | SLC6A4 4537/4885HTR2A 4618/4885HRH3 2212/4885 |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | CBR1, OGFR, CBR3 | SLC6A4 2002/4885HTR2A 1502/4885HRH3 275/4885 |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | SLC6A4 4825/4885HTR2A 3555/4885HRH3 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.